Truist raised the firm’s price target on Fresenius Medical (FMS) to $28 from $26 and keeps a Hold rating on the shares. Despite the non-discretionary nature of the service and solid cash flow, improving volume trends remain critical amid a mixed environment marked by sluggish admissions, mortality, and missed treatments, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan Stanley
- Cautious Outlook for Fresenius Medical Care Amid Sector Challenges and Persistent Headwinds
- Fresenius Medical Care Appoints New Global Chief Medical Officer
- Fresenius Medical names Charles Hugh-Jones as Global Chief Medical Officer
- Fresenius Medical price target lowered to EUR 37.40 from EUR 41.50 at JPMorgan